Chime Biologics has Signed a Contract with Wuhan East Lake High-tech Zone of Investing $900 Million to Build the World’s Most Competitive Biomedical CDMO Commercial Base

WUHAN, Apr. 8, 2020 — Chime Biologics, formerly “Xikang (Wuhan) biopharmaceutical Co., Ltd.”, today participated the special event of Wuhan “Cloud Investment” hosted by Wuhan Municipal People’s Government. Witnessed by Provincial, municipal and district leaders, Chime Biologics signed a contract with Wuhan East Lake High-tech Zone, and the two sides will jointly promote Chime Biologics’ large-scale biological world-class Contract Development and Manufacturing Organization (CDMO) factory to launch and start as soon as possible.

The project plans to invest $900 million and acquire about 270 mu of land. After the the project is completed Chime Biologics will have a world-class CDMO facility, which has an integrated system with a great many 2,000L single-use bioreactors and world-class 10,000L stainless steel bioreactors, which total capacity will exceed 140,000L.

In addition to expanding the capacity required as a traditional CDMO service model, Chime Biologics will create a new service model, providing the personalized customized service of the biopharmaceutical factory,  including financing incorporation, production services, plant construction and operation management according to the needs of the commercial production projects of the customers.

After the launch of the project, Chime Biologics will be one of the most competitive biopharmaceutical scale CDMO platforms in the world. It will provide one stop comprehensive solution supporting our global customers from early-stage biopharmaceutical development to late-stage clinical and commercial manufacturing. Thanks to MAH system (the Marketing Authorization Holder), more and more innovative biopharmaceuticals will be produced in Wuhan’s BioLake biotech industry development zone of China.

” The outbreak of the COVID-19 epidemic has a great impact on various industries around the world. But the more we are in this situation, the more we have to strengthen our confidence and fulfill our mission. Chime Biologics has always been based on the concept of serving customers. In order to meet the needs of more customers, we have launched a larger CDMO facility construction plan.”  said Mr. James Huang, Executive Chairman and CEO of Chime Biologics. “We will also adhere to the principles of high quality, high standard and high efficiency, as always, providing first-class CDMO services to customers worldwide.”